1. 5-amino levulinic acid inhibits SARS-CoV-2 infection in vitro.
- Author
-
Sakurai Y, Ngwe Tun MM, Kurosaki Y, Sakura T, Inaoka DK, Fujine K, Kita K, Morita K, and Yasuda J
- Subjects
- Animals, Antiviral Agents administration & dosage, COVID-19 prevention & control, COVID-19 virology, Caco-2 Cells, Chlorocebus aethiops, Citric Acid, Dose-Response Relationship, Drug, Drug Evaluation, Preclinical methods, Ferrous Compounds pharmacology, Humans, Levulinic Acids administration & dosage, Vero Cells, Aminolevulinic Acid, Antiviral Agents pharmacology, Levulinic Acids pharmacology, COVID-19 Drug Treatment
- Abstract
The current COVID-19 pandemic requires urgent development of effective therapeutics. 5-amino levulinic acid (5-ALA) is a naturally synthesized amino acid and has been used for multiple purposes including as an anticancer therapy and as a dietary supplement due to its high bioavailability. In this study, we demonstrated that 5-ALA treatment potently inhibited infection of SARS-CoV-2, a causative agent of COVID-19, in cell culture. The antiviral effects could be detected in both human and non-human cells, without significant cytotoxicity. Therefore, 5-ALA is worth to be further investigated as an antiviral drug candidate for COVID-19., Competing Interests: Declaration of competing interest The authors declare no known competing financial interests or no personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2021 Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF